Genelabs/Watson Aslera Lupus Deal Includes $30.5 Mil. In Up-Front Payments
Executive Summary
Watson Pharmaceuticals is investing $30.5 mil. up front to help Genelabs Technologies bring its systemic lupus erythematosus treatment Aslera (prasterone) to market, the companies jointly announced Nov. 13.
You may also be interested in...
Genelabs Requests Meeting With FDA After Aslera "Not-Approvable" Letter
Genelabs plans to meet with FDA to discuss the NDA for its lupus treatment Aslera (prasterone) following receipt of a "not-approvable" letter June 26.
Genelabs Requests Meeting With FDA After Aslera "Not-Approvable" Letter
Genelabs plans to meet with FDA to discuss the NDA for its lupus treatment Aslera (prasterone) following receipt of a "not-approvable" letter June 26.
Watson Moves Reps To Women's, General Divisions For Branded Launches
Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.